Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS)

Daojun Mo, Dana Sue Hardin, Eva Marie Erfurth, Shlomo Melmed, Daojun Mo, Dana Sue Hardin, Eva Marie Erfurth, Shlomo Melmed

Abstract

Background: The French Safety and Appropriateness of Growth Hormone treatments in Europe (SAGhE) cohort has raised concern of increased mortality risk during follow-up into adulthood in certain patients who had received growth hormone (GH) treatment during childhood. The Hypopituitary Control and Complications Study monitored mortality and morbidity of adult GH-deficient patients including those with childhood-onset GH deficiency (COGHD) who received GH treatment as children.

Purpose: Evaluate risk of mortality, cancer, myocardial infarction (MI) and stroke in a prospective observational study.

Methods: COGHD patients [n = 1,204, including 389 diagnosed with idiopathic COGHD (ICOGHD)] had received pediatric GH treatment. Standardized mortality ratios (SMRs), and cancer standardized incidence ratios (SIRs) in patients without a prior cancer were estimated relative to reference populations. Crude incidence rates were estimated for MI and stroke.

Results: No increased mortality or cancer incidence was observed, as compared with reference populations, during a follow-up of 3.7 ± 3.3 years (mean ± SD). The overall SMR for COGHD was 1.14 [95 % confidence interval (CI) 0.55-2.10], and for ICOGHD, 0.33 (0.01-1.84). The overall cancer SIR for COGHD was 0.27 (0.01-1.50), and for ICOGHD, 0.00 (0.00-2.45). No incident case of MI was reported. The crude stroke incidence rate [181.3 per 100,000 person-years] in COGHD patients was consistent with the rates reported in reference populations. No incident case of stroke was identified in ICOGHD patients who are presumed to have no increased stroke risk factors.

Conclusions: The results indicate no increased risk of mortality or incidence of cancer, stroke, or MI in adult GH-deficient patients who had previously received pediatric GH treatment.

Trial registration: ClinicalTrials.gov NCT01088399.

References

    1. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, Coste J. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97(2):416–425. doi: 10.1210/jc.2011-1995.
    1. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken G, Hokken-Koelega A. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97(2):E213–E217. doi: 10.1210/jc.2011-2882.
    1. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, Radovick S, Saenger P, Savage MO, Wit JM. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab. 2012;97:68–72. doi: 10.1210/jc.2011-2294.
    1. Sperling MA. Long-term therapy with growth hormone: bringing sagacity to SAGhE. J Clin Endocrinol Metab. 2012;97:81–83. doi: 10.1210/jc.2011-3271.
    1. Webb SM, Strasburger CJ, Mo D, Hartman ML, Melmed S, Jung H, Blum WF, Attanasio AF, HypoCCS International Advistory Board Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab. 2009;94:392–399. doi: 10.1210/jc.2008-0713.
    1. Child CJ, Zimmermann AG, Woodmansee WW, Green DM, Li JJ, Jung H, Erfurth EM, Robison LL, HypoCCS International Advisory Board Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol. 2011;165(2):217–223. doi: 10.1530/EJE-11-0286.
    1. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW, International HypoCCS Advisory Board Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing’s disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab. 2011;95:630–638. doi: 10.1210/jc.2009-0806.
    1. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, Blum WF, Robison LL, GeNeSIS and HypoCCS International Advisory Boards Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013;168(4):565–573. doi: 10.1530/EJE-12-0967.
    1. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P, International Hypopituitary Control Complications Study Advisory Board Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010;95(1):74–81. doi: 10.1210/jc.2009-1326.
    1. Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR, HypoCCS International Advisory Board Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab. 2011;96(7):2255–2261. doi: 10.1210/jc.2011-0448.
    1. Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373–380.
    1. Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1–406.
    1. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B, Xu J (2010) Deaths: final data for 2007. National vital statistics reports, vol 58, no. 19. National Center for Health Statistics, Hyattsville, pp 1–135
    1. World Health Organization European Detailed Mortality Database. “Indicators.” . Accessed 22 Mar 2011
    1. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds) (2007) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda. . Accessed 26 Nov 2010
    1. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide (2002 estimates). International Agency for Research on Cancer. . Accessed 22 Mar 2011
    1. Westfall P, Hochberg Y, Rom D, Wolfinger R, Tobias R (2004) Concepts and basic methods for multiple comparisons and tests. In: Multiple comparisons and multiple tests using the SAS system, 2nd edn, 3rd printing. SAS Institute Inc, Cary, pp 13–40
    1. Kleindorfer DO, Khoury J, Moomaw CJ, Alwell K, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Broderick JP, Kissela BM. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study. Stroke. 2010;41(7):1326–1331. doi: 10.1161/STROKEAHA.109.575043.
    1. European Registers of Stroke (EROS) Investigators. Heuschmann PU, Di Carlo A, Bejot Y, Rastenyte D, Ryglewicz D, Sarti C, Torrent M, Wolfe CD. Incidence of stroke in Europe at the beginning of the 21st century. Stroke. 2009;40(5):1557–1563. doi: 10.1161/STROKEAHA.108.535088.
    1. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46(1):75–81. doi: 10.1046/j.1365-2265.1997.d01-1749.x.
    1. Brown P, Gajdusek DC, Gibbs CJ, Jr, Asher DM. Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med. 1985;313:728–731. doi: 10.1056/NEJM198509193131205.
    1. Stochholm K, Juul S, Christiansen JS, Gravholt CH. Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. Eur J Endocrinol. 2012;167(5):663–670. doi: 10.1530/EJE-11-1084.
    1. Kitamura A, Sato S, Kiyama M, Imano H, Iso H, Okada T, Tanigawa T, Yamagishi K, Nakamura M, Konishi M, Shimamoto T, Iida M, Komachi Y. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol. 2008;52(1):71–79. doi: 10.1016/j.jacc.2008.02.075.
    1. Graham MR, Evans P, Davies B, Baker JS. Arterial pulse wave velocity, inflammatory markers, pathological GH and IGF states, cardiovascular and cerebrovascular disease. Vasc Health Risk Manag. 2008;4(6):1361–1371.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143–3421
    1. de Boer H, van der Veen EA. Why retest young adults with childhood-onset growth hormone deficiency? J Clin Endocrinol Metab. 1997;82(7):2032–2036. doi: 10.1210/jcem.82.7.4101.
    1. Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab. 2007;92(4):1195–1200. doi: 10.1210/jc.2007-0167.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa